clinical trial · NCT06232109
Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects
Asceneuron S.A.·phase1·completed·n = 50
Drug Drug InteractionFluvoxamineItraconazoleParoxetineASN51
brief summary
The drug-drug interaction study has been designed to investigate the effect of Fluvoxamine, Itraconazole and Paroxetine on the pharmacokinetics of ASN51
started
Feb 22, 2024
primary completion
Jul 3, 2024
completion
Jul 3, 2024
last updated
Dec 18, 2024
official title
Phase 1, Open-Label, Parallel Group Drug-Drug Interaction Study to Assess the Effect of Fluvoxamine (CYP2C19 Inhibitor), Itraconazole (CYP3A4 Inhibitor) and Paroxetine (CYP2D6 Inhibitor) on the Pharmacokinetics of ASN51 in Healthy Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol